RxDoctor Payments Data

Bernard Kurecki, MD

Family Medicine · Huntsville, ALNPI 1487604336

Payments from drug & device makers

$1,642in general payments, 2019–2025

Across 89 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$275
  • Amgen$246
  • GSK$239
  • Novo Nordisk$169
  • Antares Pharma, Inc.$124
  • Gilead$122
  • plus $467 from 12 others

What the payments were for

  • Food & beverage$1,63099%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,642 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$155,122
Medicare patients
347
Services billed
2,656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$121,324
JardianceEmpagliflozin97$118,003
OzempicSemaglutide66$105,724
EliquisApixaban90$87,561
JanuviaSitagliptin Phosphate33$40,759
LinzessLinaclotide50$34,174
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$30,273
FarxigaDapagliflozin Propanediol19$20,587
LyricaPregabalin15$19,641
Repatha SureclickEvolocumab16$16,257
VascepaIcosapent Ethyl15$13,967
Tresiba Flextouch U-100Insulin Degludec19$13,569
Atorvastatin Calcium549$6,957
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,864
Rosuvastatin Calcium357$6,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$29$121,32484 claims
Boehringer IngelheimJardiance$275$118,00397 claims
PfizerEliquis, Lyrica$45$107,202105 claims
Novo NordiskOzempic$169$105,72466 claims
AbbVieLinzess$29$34,17450 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$29$33,16842 claims
GSKTrelegy Ellipta$239$30,27326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →